Cytek Biosciences (CTKB) News Today $4.10 -0.12 (-2.84%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$4.11 +0.01 (+0.12%) As of 03/25/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Cytek Biosciences (NASDAQ:CTKB) Trading Up 2.2% - Time to Buy?Cytek Biosciences (NASDAQ:CTKB) Trading 2.2% Higher - Time to Buy?March 22, 2025 | marketbeat.comCytek Biosciences' (CTKB) "Overweight" Rating Reiterated at StephensMarch 22, 2025 | americanbankingnews.comCytek Biosciences (NASDAQ:CTKB) Hits New 12-Month Low - Should You Sell?Cytek Biosciences (NASDAQ:CTKB) Sets New 1-Year Low - What's Next?March 21, 2025 | marketbeat.comCytek Biosciences Launches Next-Generation Muse Micro Cell Analyzer to Transform Flow Cytometry AccessibilityMarch 21, 2025 | nasdaq.comCytek Biosciences (NASDAQ:CTKB) Receives "Overweight" Rating from StephensStephens reiterated an "overweight" rating and issued a $6.00 price target on shares of Cytek Biosciences in a research note on Wednesday.March 20, 2025 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Shares Purchased by Royce & Associates LPRoyce & Associates LP lifted its position in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 159.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 470,819 shares of the company's stock after acquiringMarch 20, 2025 | marketbeat.comCytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro SystemMarch 18, 2025 | globenewswire.comGlobeflex Capital L P Purchases Shares of 84,434 Cytek Biosciences, Inc. (NASDAQ:CTKB)Globeflex Capital L P purchased a new stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 84,434 shares of the company's stock, valuedMarch 16, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Sets New 1-Year Low - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Hits New 1-Year Low - Should You Sell?March 13, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Here's WhyMarch 12, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Price Target Lowered to $8.00 at Piper SandlerPiper Sandler decreased their target price on Cytek Biosciences from $8.50 to $8.00 and set an "overweight" rating for the company in a research note on Tuesday.March 5, 2025 | marketbeat.comCytek Biosciences (CTKB) Expected to Announce Quarterly Earnings on WednesdayCytek Biosciences (NASDAQ:CTKB) will be releasing earnings after the market closes on Wednesday, March 12. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666441)March 5, 2025 | marketbeat.comCytek Biosciences price target lowered to $8 from $8.25 at Piper SandlerMarch 4, 2025 | markets.businessinsider.comCytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2024 Earnings Call TranscriptMarch 3, 2025 | msn.comCytek Biosciences (NASDAQ:CTKB) Sets New 52-Week Low - Should You Sell?Cytek Biosciences (NASDAQ:CTKB) Hits New 52-Week Low - What's Next?March 1, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPSCytek Biosciences (NASDAQ:CTKB - Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of $0.05 by $0.02. Cytek Biosciences had a negative return on equity of 2.58% and a negative net margin of 5.05%.February 28, 2025 | marketbeat.comCytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call TranscriptFebruary 28, 2025 | seekingalpha.comCytek Biosciences sees FY25 revenue $204M-$212M, consensus $216.52MFebruary 27, 2025 | markets.businessinsider.comCytek Biosciences reports Q4 revenue $57.48M, consensus $59.38MFebruary 27, 2025 | markets.businessinsider.comCytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 OutlookFebruary 27, 2025 | globenewswire.comEarnings To Watch: Cytek Biosciences Inc (CTKB) Reports Q4 2024 ResultFebruary 26, 2025 | finance.yahoo.comCytek Biosciences (CTKB) Projected to Post Quarterly Earnings on ThursdayCytek Biosciences (NASDAQ:CTKB) will be releasing earnings after the market closes on Thursday, February 27, Financial Modeling Prep reports.February 21, 2025 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Sees Significant Decline in Short InterestCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 3,170,000 shares, a decrease of 8.6% from the January 15th total of 3,470,000 shares. Approximately 2.7% of the shares of the stock are short sold. Based on an average daily volume of 799,100 shares, the days-to-cover ratio is presently 4.0 days.February 18, 2025 | marketbeat.comCytek BiosciencesFebruary 14, 2025 | forbes.comCytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025February 13, 2025 | globenewswire.comCytek Biosciences (NASDAQ:CTKB) Sees Unusually-High Trading Volume - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Sees Strong Trading Volume - What's Next?February 11, 2025 | marketbeat.comCytek Biosciences to Participate in Upcoming Investor ConferencesFebruary 5, 2025 | globenewswire.comCytek Biosciences (NASDAQ:CTKB) Stock Price Down 4% - Here's WhyCytek Biosciences (NASDAQ:CTKB) Trading Down 4% - Time to Sell?February 4, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Trading Up 5% - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Shares Up 5% - Should You Buy?February 3, 2025 | marketbeat.comCytek Biosciences price target raised to $5.25 from $4.50 at Goldman SachsFebruary 2, 2025 | markets.businessinsider.comGoldman Sachs cuts Cytek Biosciences stock rating to sellJanuary 31, 2025 | msn.comCytek Biosciences downgraded to Sell from Buy at Goldman SachsJanuary 31, 2025 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - What's Next?Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - What's Next?January 31, 2025 | marketbeat.comThe Goldman Sachs Group Downgrades Cytek Biosciences (NASDAQ:CTKB) to SellThe Goldman Sachs Group downgraded Cytek Biosciences from a "buy" rating to a "sell" rating and reduced their target price for the company from $7.00 to $4.50 in a research report on Friday.January 31, 2025 | marketbeat.comPiper Sandler Remains a Buy on Cytek Biosciences (CTKB)January 31, 2025 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Shares Down 5.5% - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Trading Down 5.5% - Time to Sell?January 29, 2025 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) is largely controlled by institutional shareholders who own 53% of the companyJanuary 27, 2025 | finance.yahoo.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Should You Sell?Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Here's What HappenedJanuary 17, 2025 | marketbeat.comCytek Biosciences sees FY24 revenue $200M-$201M, consensus $204.71MJanuary 16, 2025 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Time to Sell?Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Should You Sell?January 15, 2025 | marketbeat.comCytek Biosciences shares take a hit after Q4 sales miss estimatesJanuary 15, 2025 | in.investing.comCytek Biosciences Shares Fall On Low Preliminary 4Q RevenueJanuary 15, 2025 | marketwatch.comCytek Biosciences Announces Preliminary Full Year 2024 Revenue ResultsJanuary 15, 2025 | markets.businessinsider.comMorgan Stanley Sticks to Their Hold Rating for Cytek Biosciences (CTKB)January 14, 2025 | markets.businessinsider.comBarclays PLC Has $1.12 Million Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB)Barclays PLC raised its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 333.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 201,359 shares of the company's stock after buyingJanuary 14, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Trading 5.9% Higher - Time to Buy?Cytek Biosciences (NASDAQ:CTKB) Shares Up 5.9% - Should You Buy?January 13, 2025 | marketbeat.comUpgrading Cytek Biosciences Stock On An Upcoming CatalystJanuary 9, 2025 | seekingalpha.comCytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | globenewswire.comCytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest UpdateCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 3,690,000 shares, a drop of 6.6% from the November 30th total of 3,950,000 shares. Approximately 3.2% of the company's stock are sold short. Based on an average trading volume of 661,700 shares, the short-interest ratio is currently 5.6 days.December 31, 2024 | marketbeat.comCytek Biosciences board approves $50M stock repurchase programDecember 31, 2024 | markets.businessinsider.com Remove Ads Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address CTKB Media Mentions By Week CTKB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTKB News Sentiment▼0.150.71▲Average Medical News Sentiment CTKB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTKB Articles This Week▼82▲CTKB Articles Average Week Remove Ads Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 10x Genomics News Transcat News EyePoint Pharmaceuticals News Standard BioTools News Senseonics News Allient News Quantum-Si News Aehr Test Systems News Quanterix News 908 Devices News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTKB) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
